Amelioration of post-ischemic lung reperfusion injury by prostaglandin E1.

To reduce ischemia-reperfusion injury, a number of clinical lung transplant programs employ prostaglandin E1 (PGE1) or prostacyclin (PGI2) before donor lung flush and harvest. The effect of prostaglandins on the reperfusion component of this ischemia-reperfusion complex is unknown. We investigated the effect of PGE1 given only during the period of reperfusion, on ischemic lung injury in an in situ rabbit model. To examine the mechanisms involved, we measured pulmonary hemodynamics as well as myeloperoxidase, circulating platelet, and tumor necrosis factor (TNF) values. Two hours of warm ischemia of the left lung was produced in anesthetized New Zealand white rabbits. The animals were randomly allocated into four groups based on treatment received only during reperfusion: PGE1, PGI2, nitroprusside (NP), or no treatment (controls). After 2 h of reperfusion, PaO2 in the PGE1 group was significantly higher (423 +/- 52.7 mm Hg) than in all other groups (PGI2, 239 +/- 43.4, p < 0.05; NP, 146 +/- 14.2 p < 0.01; controls, 74 +/- 19.1 mm Hg, p < 0.01), despite similar pulmonary vascular resistance in the PGE1 and NP groups. Although lower than in the PGE1 group, PaO2 in the PGI2 group was still significantly higher than that in controls. Wet/dry lung weight ratios were significantly lower in the PGE1 and PGI2 groups (6.5 +/- 0.2 [p < 0.01] and 6.9 +/- 0.6 [p < 0.05], respectively, versus 8.2 +/- 0.1 in controls). There were no significant differences in plasma TNF levels, platelet sequestration across the lungs, or lung myeloperoxidase activity in the four groups.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  Arthur S Slutsky,et al.  Reliable thirty-hour lung preservation by donor lung hyperinflation. , 1992, The Journal of thoracic and cardiovascular surgery.

[2]  M K Pasque,et al.  The evolution of single lung transplantation for emphysema. The Washington University Lung Transplant Group. , 1991, The Journal of thoracic and cardiovascular surgery.

[3]  G. Patterson,et al.  Comparison of outcomes of double and single lung transplantation for obstructive lung disease. The Toronto Lung Transplant Group. , 1991, The Journal of thoracic and cardiovascular surgery.

[4]  H. Ayabe,et al.  Twenty-four-hour canine lung preservation using UW solution. , 1991, Transplantation.

[5]  W. K. Adkins,et al.  Effect of ischemia reperfusion or hypoxia reoxygenation on lung vascular permeability and resistance. , 1990, Journal of applied physiology.

[6]  A. Romaschin,et al.  Complement activation and white cell sequestration in postischemic skeletal muscle. , 1990, The American journal of physiology.

[7]  B. Griffith,et al.  Primary graft failure following pulmonary transplantation. , 1990, Transplantation.

[8]  C. S. Campbell,et al.  AMELIORATION OF LUNG ISCHEMIC INJURY WITH PROSTACYCLIN , 1990, Transplantation.

[9]  R. Strieter,et al.  Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. , 1990, The Journal of clinical investigation.

[10]  M. Johnston,et al.  The effect of prostacyclin as a constituent of a preservation solution in protecting lungs from ischemic injury because of its vasodilatory properties. , 1990, Transplantation.

[11]  Toledo-Pereyra Lh,et al.  Acute mesenteric small bowel ischemia in the rat. I. Protective effect of naloxone. , 1990 .

[12]  B. Griffith,et al.  Organ procurement for pulmonary transplantation. , 1989, The Annals of thoracic surgery.

[13]  L. Rubin,et al.  Effects of a Thromboxane A2 Analogue and Prostacyclin on Lung Fluid Balance in Newborn Lambs , 1989, Circulation research.

[14]  G. Patterson,et al.  A method for safe twelve-hour pulmonary preservation. , 1989, The Journal of thoracic and cardiovascular surgery.

[15]  K. Yagyu,et al.  The effect of prostacyclin on reperfusion injury after pulmonary ischemia. , 1989, Transplantation proceedings.

[16]  D. Remick,et al.  Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. , 1988, The Journal of biological chemistry.

[17]  J. Wallwork,et al.  DISTANT PROCUREMENT OF ORGANS FOR CLINICAL HEART‐LUNG TRANSPLANTATION USING A SINGLE‐FLUSH TECHNIQUE , 1987, Transplantation.

[18]  E. Stinson,et al.  Clinical heart-lung preservation with prostaglandin E-1. , 1987, Transplantation proceedings.

[19]  T. English,et al.  Distant procurement and preservation of heart-lung homografts. , 1987, Transplantation proceedings.

[20]  L. Rubin,et al.  Prostacyclin and PGE1 treatment of pulmonary hypertension. , 1987, The American review of respiratory disease.

[21]  I. Yada,et al.  Effect of prostaglandin E1 on the prolongation of rat cardiac allograft survival. , 1987, Transplantation Proceedings.

[22]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[23]  J. Gamble,et al.  Stimulation of neutrophils by tumor necrosis factor. , 1986, Journal of immunology.

[24]  S. Goldblum,et al.  Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. , 1985, Journal of applied physiology.

[25]  B. Aggarwal,et al.  Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. , 1985, Journal of immunology.

[26]  W. Marasco,et al.  Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. , 1984, The American journal of pathology.

[27]  J. Vane Nobel lecture. Adventures and excursions in bioassay--the stepping stones to prostacyclin. , 1983, Postgraduate medical journal.

[28]  J. Vane Adventures and excursions in bioassay: the stepping stones to prostacylin , 1983, British journal of pharmacology.

[29]  T. Strom,et al.  PROSTAGLANDIN AS AN EFFECTIVE ANTIREJECTION THERAPY IN RAT RENAL ALLOGRAFT RECIPIENTS , 1983, Transplantation.

[30]  P. Ward,et al.  Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. , 1980, Journal of immunology.

[31]  A. Robert Cytoprotection by prostaglandins. , 1979, Gastroenterology.

[32]  A. Malik,et al.  Release of tumor necrosis factor after pulmonary artery occlusion and reperfusion. , 1993, The American review of respiratory disease.

[33]  R. Pearl,et al.  Effects of prostaglandin E1 and hydralazine on the longitudinal distribution of pulmonary vascular resistance during vasoconstrictor pulmonary hypertension in sheep. , 1992, Anesthesiology.

[34]  L. Toledo-Pereyra,et al.  Twenty-four hour heart-lung preservation and oxygen free radical scavengers. , 1987, Transplantation Proceedings.